

ACOG PRACTICE BULLETIN

Clinical Management Guidelines for Obstetrician–Gynecologists

NUMBER 221

(Replaces Practice Bulletin No. 161, February 2016)

Committee on Practice Bulletins—Obstetrics. This Practice Bulletin was developed by the Committee on Practice Bulletins—Obstetrics in collaboration with Gayle Olson Koutrouvelis, MD.

INTERIM UPDATE: This Practice Bulletin is updated as highlighted to reflect a limited, focused change in the evidence regarding external cephalic version in women with a previous cesarean birth and the evidence on the inverse relationship between hospital cesarean birth rate and successful external cephalic version. In addition, there is a new Level B recommendation for the consideration of the use of neuraxial analgesia in combination with tocolytic therapy to increase external cephalic version success rate.

External Cephalic Version

In the United States, there is a widespread belief that the overall cesarean birth rate is higher than necessary. Efforts are being directed toward decreasing the number of these procedures, in part by encouraging physicians to make changes in their management practices. Because breech presentations are associated with a high rate of cesarean birth, there is renewed interest in techniques such as external cephalic version (ECV) and vaginal breech delivery. The purpose of this document is to provide information about ECV by summarizing the relevant evidence presented in published studies and to make recommendations regarding its use in obstetric practice.

Background

Breech presentation occurs in approximately 3–4% of term pregnancies (1), and there is a high cesarean birth rate for breech presentation (2). External cephalic version provides a means of reducing cesarean births, but implementation of ECV varies, with an estimated 20–30% of eligible women not being offered ECV (3, 4). External cephalic version involves applying pressure to a woman's abdomen to turn the fetus in either a forward or backward roll to achieve a vertex presentation. The goal of ECV is to increase the proportion of vertex presentations among fetuses that were formerly in the breech position near term. Once a vertex presentation is achieved, the chances for a vaginal delivery increase.

If an ECV attempt is not successful and breech presentation persists, the decision regarding mode of delivery should depend on the expertise of the health care provider. Thus, a planned term singleton breech vaginal delivery may be reasonable in some cases with full patient counseling and consent and following specific management protocols (5).

Clinical Considerations and Recommendations

► Which patients are candidates for external cephalic version?

Fetal presentation should be assessed and documented beginning at 36 0/7 weeks of gestation to allow for ECV (6). Thereafter, patients who have reached at least 37 0/7 weeks of gestation are preferred candidates for ECV for several reasons. First, if spontaneous version is going to occur, it is likely to have taken place by 37 0/7 weeks of gestation (7, 8). Second, risk of a spontaneous reversion after ECV is decreased after 37 0/7 weeks compared with ECV earlier in gestation. Preterm ECV attempts may be associated with high initial success rates but also with higher reversion rates, necessitating additional procedures (9). In an unblinded multicenter randomized controlled trial, a small but significant difference in noncephalic presentation at birth was noted for early ECV (34 0/7–35 6/7 weeks of gestation) compared with



ECV at or after 37 0/7 weeks of gestation (41.1% versus 49.1%) (relative risk [RR], 0.84; 95% confidence interval [CI], 0.75–0.94; $P=.002$), with no differences in rate of cesarean birth or preterm birth (10). A more recent review of pooled data from three studies that included 1,906 participants suggested that earlier ECV (at 34–35 weeks of gestation) compared with ECV at early term (37–38 weeks of gestation) reduced noncephalic presentation at birth (RR, 0.81; 95% CI, 0.74–0.90) (11). Further analysis of 1,888 of the participants also noted reduced failure to achieve a cephalic vaginal birth (RR, 0.90; 95% CI, 0.83–0.97), but an increased risk of preterm labor (RR, 1.51; 95% CI, 1.03–2.21) (11). The possible risk of preterm birth needs to be weighed against any benefits of ECV. Third, if complications arise during an attempted ECV, emergency cesarean delivery of a term infant can be accomplished (12).

There is **limited** information concerning ECV attempts among women who have a preexisting uterine scar or who undergo the procedure during the early stages of labor. Information concerning ECV attempts among women who have a preexisting uterine scar are from retrospective case-control analyses. Seven studies were single institution comparisons of women undergoing ECV with one previous cesarean birth (total $n = 500$) compared with multiparous women without a previous cesarean birth (13–19). An eighth trial analyzed a large administrative dataset from the United States based on U.S. birth certificates from 2012 to 2014, with 715 women undergoing ECV with one previous cesarean birth (20). Results of these studies were mixed, with a significantly higher rate of successful ECV in women with a previous cesarean birth in one study (13), a significantly lower rate in three studies (18, 19, 20), and no significant difference in four studies (14–17). Yet, the overall rate of successful ECV in women with a previous cesarean birth ranged from 50% to 84%. No cases of uterine rupture during ECV in women with a previous cesarean birth were reported in any of the four trials.

Scattered reports of successful ECV performed during early labor have been noted (9, 21). Data derived from the Nationwide Inpatient Sample from 1998 to 2011 that analyzed attempted ECV performed *during* the delivery admission noted an ECV success rate of 65% (22). This resulted in a significantly lower cesarean birth rate and a lower likelihood of hospital stay greater than 7 days when compared with women who had persistent breech presentation at the time of delivery.

External cephalic version is considered to be contraindicated if vaginal delivery is not clinically appropriate (23). The data are not adequate to clearly establish absolute or relative contraindications to ECV, and in many cases they may need to be individualized.

► *What are the benefits and risks of external cephalic version?*

The immediate benefit of successful ECV is an increased probability that the fetus will be in a vertex presentation for delivery. The ultimate goal is an uncomplicated vaginal delivery. Reports from published studies indicate that there are fewer cesarean births among women who have undergone successful ECV compared with women who have not attempted ECV (12, 24, 22, 25). Compared with women with persistent breech presentations, women who underwent successful ECV had lower hospital charges, reduced total length of hospital stay, and lower odds of developing endometritis, sepsis, and length of hospital stay greater than 7 days (22). A recent review assessing the effects of ECV on breech presentation at or near term compared with no attempted ECV pooled data from eight studies involving 1,308 participants. This review noted a significant reduction in noncephalic presentation at birth (RR, 0.42; 95% CI, 0.29–0.61), a reduction in failure to achieve cephalic vaginal birth (RR, 0.46; 95% CI, 0.33–0.62), and a reduction in cesarean births (RR, 0.57; 95% CI, 0.40–0.82) (1). No differences were noted for low Apgar score, low umbilical vein pH, or neonatal death (1).

Adverse events after ECV have been reported and include abruptio placentae, umbilical cord prolapse, rupture of membranes, stillbirth, and fetomaternal hemorrhage; all occurred at rates of less than 1% (26, 27). Fetal heart rate changes during attempted ECVs are not uncommon, but the heart rate usually stabilizes when the procedure is discontinued (28–31). A report from Copenhagen described two cases of intrauterine death 2 weeks and 5 weeks after ECV among 316 women and one instance of premature partial separation of the placenta 2 days after an unsuccessful ECV attempt (32). The two deaths could not be causally linked to ECV. In a study including pregnant women at 36 weeks of gestation or earlier, two cases of abruptio placentae and one case of premature labor occurred shortly after ECV, resulting in one neonatal and two fetal deaths (33). A follow-up study was conducted at the same institution, but changes in management practices and selection criteria were made that caused the outcomes to be difficult to compare (24). Only term gestations were selected, and tocolytic agents as well as fetal monitoring were used during ECV attempts. No fetal deaths were causally linked to ECV. The authors concluded that ECV can substantially decrease breech presentations and the cesarean birth rate among these patients (24).

One study reported a case of abruptio placentae during an ECV attempt that required emergency cesarean delivery (34). It was the only major complication



attributed to ECV among 113 women. Although the incidence of complications associated with ECV is low, the potential is present and thus ECV should be performed where prompt evaluation and, if necessary, cesarean delivery are readily available.

► ***What are the success rates for external cephalic version, and what factors are predictive of success or failure?***

A meta-analysis of ECV-related risks concluded that the success rate for ECV ranged from 16% to 100%, with a pooled success rate of 58% and pooled complication rate of 6.1% (27). Some reports indicate a positive association between parity and successful version (12, 28, 29, 33, 35–39). A transverse or oblique presentation is associated with higher immediate success rates (35, 36, 40). There is an inverse relationship between hospital cesarean birth rate and successful ECV. Successful ECV was one-third lower among women who delivered at hospitals with total cesarean birth rates greater than 35%, compared with women who delivered at hospitals with a cesarean birth rate less than 20% (22). Although scoring systems have been developed to predict which patients are more likely to have a successful ECV attempt, opinion is divided about the usefulness of other factors in predicting successful ECV, including amniotic fluid volume, location of the placenta, and maternal weight. Moreover, these scoring systems have not been validated. Some reports indicate an association between normal or increased amounts of amniotic fluid and successful ECV (36, 38, 41, 42), whereas other reports do not (43). Two authors reported an association between successful ECV and placenta location (38, 43), but others failed to find an association (36, 40, 42). Two authors found that obesity was associated with a higher failure rate (29, 39), although others found that maternal weight was not a significant predictor of success (36, 42–44). Finally, nulliparity, advanced dilatation, fetal weight of less than 2,500 grams, anterior placenta, and low station were more often associated with failure (43, 45, 46).

► ***How does the use of tocolysis affect the success rate of external cephalic version?***

A randomized study of terbutaline found the success rate of ECV associated with use of this tocolytic to be almost double the success rate without its use (47). In the vast majority of published studies, a tocolytic agent had been used routinely (12, 24, 28, 29, 31, 32, 34, 36, 37, 40, 42, 43, 48–52) or selectively (9, 13, 53), but only in rare cases were no tocolytic agents used (33). An extensive review that evaluated interventions for ECV included 28 studies that provided data from 2,706 participants.

A subset of five studies with 459 participants revealed parenteral β -stimulant tocolysis was more effective in attaining cephalic presentation in labor (RR, 1.68; 95% CI, 1.14–2.48). A subset of six studies with 742 participants showed a reduction in cesarean births (RR, 0.77; 95% CI, 0.67–0.88), whereas a subset of four studies with 399 participants showed a lower rate of failure to achieve a cephalic vaginal delivery (RR, 0.75; 95% CI, 0.60–0.92) (54). Evidence supports the use of parenteral tocolysis to improve the success of ECV.

Data were insufficient to analyze adverse effects of β -stimulant tocolysis. However, even the small amount of data available for the use of nitric oxide donors for ECV were sufficient to discourage its use (54). Data for the use of calcium channel blockers for ECV also were insufficient (54).

► ***Does successful external cephalic version translate into lower cesarean birth rates?***

Whether ECV results in a lower cesarean birth rate for women with breech presentation who elect this procedure compared with women who do not depends on several factors. The first factor is whether the ECV is successful; women who have successful ECV have lower cesarean birth rates than those who do not (12, 28–30, 36–40, 42, 48, 55, 22, 25). Two randomized studies also have shown a significant decrease in cesarean birth rates among patients assigned to ECV compared with those not assigned to ECV (24, 29). Retrospective case-control and cohort studies have evaluated the cesarean birth rate after successful ECV when compared with women who present with spontaneous cephalic presentations (56–62). Results have been mixed with seven trials ($n = 630$) noting no significant difference in the rate of cesarean birth and nine trials ($n = 2119$) reporting significantly higher rates of cesarean birth in women who undergo a successful ECV. A meta-analysis containing trials through 2010 reported increased odds of having a cesarean birth in pregnancies after a successful ECV when compared with women who present with a fetus in the cephalic presentation (11 studies, odds ratio 2.2, 95% CI 1.7–2.8) (63). Recent reviews provide supportive evidence that ECV is associated with an overall reduction in cesarean births (1, 54). Factors that tend to lessen overall differences between ECV and non-ECV groups include spontaneous conversion of presentation from breech to vertex or vice versa, and the willingness of obstetrician–gynecologists and other obstetric care providers to perform vaginal breech deliveries. The need to perform a cesarean delivery for other indications in women who have had a successful ECV also may lessen the overall effect of ECV on the cesarean birth rate.



External cephalic version is a valuable management technique and, in a properly selected population, poses little risk to either the woman or the fetus. If successful, ECV provides a clear benefit to the woman by allowing her an opportunity for a successful vertex vaginal delivery. Because the risk of an adverse event occurring as a result of ECV is small and the cesarean birth rate is significantly lower among women who have undergone successful ECV, all women who are near term with breech presentations should be offered an ECV attempt if there are no contraindications.

► **How does the use of anesthesia affect the success rate of external cephalic version?**

Individual studies have found a significantly greater success rate for ECV associated with the use of epidural anesthesia; however, these studies may have been biased by low overall ECV success rates or physician preferences (21, 49, 64). It also has been suggested that epidural anesthesia be considered for women with a previous failed ECV attempt (65). One randomized trial addressed

the use of spinal anesthesia before the ECV attempt and found no significant difference in ECV success between the group with spinal analgesia and the group with no spinal analgesia (44% versus 42%, respectively; $P = .863$) (66). Another randomized trial noted a significant difference in ECV success between spinal analgesia plus tocolysis versus tocolysis alone (87.1% versus 57.5%, respectively; $P = .009$; 95% CI, 0.075–0.48) (67).

A meta-analysis investigated the use of regional anesthesia for ECV (68). Nine studies ($n = 934$) were available for analysis and identified that neuraxial analgesia in combination with tocolytics had a higher incidence of successful ECV (RR, 1.44; 95% CI, 1.27–1.64), cephalic presentation in labor (RR, 1.37; 95% CI, 1.08–1.73, and vaginal delivery after successful ECV (RR, 1.21; 95% CI, 1.04–1.41). Data are insufficient to conclusively evaluate neuraxial analgesia without tocolysis or to make a recommendation favoring spinal or epidural analgesia during ECV attempts. Neuraxial analgesia in combination with tocolytic therapy can be considered a reasonable intervention to increase ECV success rate.




Figure 1. An algorithm for patient management for external cephalic version. Note: All Rh-negative women who undergo an ECV attempt, whether successful or not, should receive Rh-immune globulin unless they are known to have an Rh-negative fetus, are already sensitized, or will be delivered in less than 72 hours and can have an assessment for risk of sensitization. Abbreviations: BPP, biophysical profile; ECV, external cephalic version; FHR, fetal heart rate; NST, nonstress test.



► **What is an example of a standard protocol for performing an external cephalic version?**

Before attempting ECV, an ultrasound examination is necessary to confirm the malpresentation of the fetus and rule out the presence of any anomalies that would complicate a vaginal delivery. Informed consent is needed and may include risks and benefits of the procedure as well as use of tocolysis and neuraxial analgesia if they are to be used for an ECV. Fetal well-being and contraction pattern should be assessed by a nonstress test or biophysical profile before and after the procedure (see Fig. 1). External cephalic version should be attempted only in settings in which cesarean delivery services are readily available.

One ECV technique involves lifting the breech upward from the pelvis with one hand and providing pressure on the head with the other hand to produce a forward roll. If the forward roll fails, a backward roll may be attempted. External cephalic version may be performed by one or two people. During the ECV procedure, intermittent use of ultrasonography allows for evaluation of the fetal heart rate as well as the position of the fetus. An ECV attempt should be abandoned if there is prolonged fetal bradycardia, discomfort to the patient, or if the procedure cannot be completed easily with the aforementioned maneuvers. After the ECV attempt, fetal evaluation is repeated and the patient is monitored for 30 minutes (or longer if clinically indicated). Anti-D immune globulin is administered to Rh-negative patients if delivery is not anticipated in the next 72 hours. There is no evidence to support the routine practice of immediate induction of labor in order to minimize reversion.

► **What are the cost implications of external cephalic version?**

A decision analysis measuring various cost implications calculated that the use of ECV would result in fewer cesarean births and lower costs than either scheduled cesarean delivery or trial of labor without an ECV attempt (69). Even if failed ECV attempts were followed by routine cesarean birth, the overall cesarean birth rate would be lower than that of a trial of labor without an ECV attempt. Sensitivity analysis revealed that as long as less than 52% of all breech presentations are eligible for a trial of labor, a policy of attempting ECV followed by either a trial of labor or routine cesarean delivery (for failed attempts) would be less expensive than a policy of routine cesarean delivery or trial of labor without ECV (69). Another computer-based decision model used hospital costs and quality-adjusted life years gained to determine the cost effectiveness in dollars of ECV (70).

External cephalic version appeared to be cost effective as long as the probability of success was greater than 32% (70). A decision-analysis model looking at the use of neuraxial analgesia with ECV noted that from a hospital and health care insurance payor perspective, neuraxial analgesia was cost saving when the ECV success rate exceeded 48% and 44%, respectively (71). However, with Monte Carlo simulation, ECV with neuraxial analgesia was only cost saving in less than half of scenarios. However, only direct medical costs were included in this study and the indirect cost, quality-adjusted life years gained, and effect on future pregnancies were not examined.

Summary of Recommendations

The following recommendation is based on good and consistent scientific evidence (Level A):

- Because the risk of an adverse event occurring as a result of ECV is small and the cesarean birth rate is significantly lower among women who have undergone successful ECV, all women who are near term with breech presentations should be offered an ECV attempt if there are no contraindications.

The following recommendations are based on limited or inconsistent scientific evidence (Level B):

- Fetal presentation should be assessed and documented beginning at 36 0/7 weeks of gestation to allow for ECV.
- Evidence supports the use of parenteral tocolysis to improve the success of ECV.
- Neuraxial analgesia in combination with tocolytic therapy can be considered a reasonable intervention to increase ECV success rate.

The following recommendations are based primarily on consensus and expert opinion (Level C):

- Fetal well-being and contraction pattern should be assessed by a nonstress test or biophysical profile before and after the procedure.
- External cephalic version should be attempted only in settings in which cesarean delivery services are readily available.

References

1. Hofmeyr GJ, Kulier R, West HM. External cephalic version for breech presentation at term. Cochrane Database of



- Systematic Reviews 2015, Issue 4. Art. No.: CD000083. DOI: 10.1002/14651858.CD000083.pub3. (Meta-analysis)
2. Hartnack Tharin JE, Rasmussen S, Krebs L. Consequences of the Term Breech Trial in Denmark. *Acta Obstet Gynecol Scand* 2011;90:767–71. (Level II-2)
 3. Vlemmix F, Rosman AN, te Hoven S, van de Berg S, Fleuren MA, Rijnders ME, et al. Implementation of external cephalic version in the Netherlands: a retrospective cohort study. *Birth* 2014;41:323–9. (Level II-2)
 4. Caukwell S, Joels LA, Kyle PM, Mills MS. Women's attitudes towards management of breech presentation at term. *J Obstet Gynaecol* 2002;22:486–8. (Level II-2)
 5. Mode of term singleton breech delivery. ACOG Committee Opinion No. 745. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2018;132:e60–3. (Level III)
 6. Safe prevention of the primary cesarean delivery. Obstetric Care Consensus No. 1. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2014;123:693–711. (Level III)
 7. Hickok DE, Gordon DC, Milberg JA, Williams MA, Darling JR. The frequency of breech presentation by gestational age at birth: a large population-based study. *Am J Obstet Gynecol* 1992;166:851–2. (Level II-2)
 8. Westgren M, Edvall H, Nordstrom L, Svalenius E, Ransam J. Spontaneous cephalic version of breech presentation in the last trimester. *Br J Obstet Gynaecol* 1985;92:19–22. (Level II-3)
 9. Kornman MT, Kimball KT, Reeves KO. Preterm external cephalic version in an outpatient environment. *Am J Obstet Gynecol* 1995;172:1734–8; discussion 1738–41. (Level II-2)
 10. Hutton EK, Hannah ME, Ross SJ, Delisle MF, Carson GD, Windrim R, et al. The Early External Cephalic Version (ECV) 2 Trial: an international multicentre randomised controlled trial of timing of ECV for breech pregnancies. Early ECV2 Trial Collaborative Group. *BJOG* 2011;118:564–77. (Level I)
 11. Hutton EK, Hofmeyr GJ, Dowswell T. External cephalic version for breech presentation before term. *Cochrane Database of Systematic Reviews* 2015, Issue 7. Art. No.: CD000084. DOI: 10.1002/14651858.CD000084.pub3. (Meta-analysis)
 12. Goh JT, Johnson CM, Gregora MG. External cephalic version at term. *Aust N Z J Obstet Gynaecol* 1993;33:364–6. (Level II-2)
 13. Flamm BL, Fried MW, Lonky NM, Giles WS. External cephalic version after previous cesarean section. *Am J Obstet Gynecol* 1991;165:370–2. (Level I)
 14. Sela HY, Fiegenberg T, Ben-Meir A, Elchalal U, Ezra Y. Safety and efficacy of external cephalic version for women with a previous cesarean delivery. *Eur J Obstet Gynecol Reprod Biol* 2009;142:111–4. (Level III)
 15. Abenhaim HA, Varin J, Boucher M. External cephalic version among women with a previous cesarean delivery: report on 36 cases and review of the literature. *J Perinat Med* 2009;37:156–60. (Level II-2)
 16. Burgos J, Cobos P, Rodriguez L, Osuna C, Centeno MM, Martinez-Astorquiza T, et al. Is external cephalic version at term contraindicated in previous caesarean section? A prospective comparative cohort study. *BJOG* 2014;121:230–5; discussion 235. (Level II-2)
 17. Keepanasseril A, Anand K, Soundara Raghavan S. Matched cohort study of external cephalic version in women with previous cesarean delivery. *Int J Gynaecol Obstet* 2017;138:79–83. (Level II-2)
 18. Weill Y, Pollack RN. The efficacy and safety of external cephalic version after a previous caesarean delivery. *Aust N Z J Obstet Gynaecol* 2017;57:323–6. (Level II-2)
 19. Impey OR, Greenwood CE, Impey LW. External cephalic version after previous cesarean section: a cohort study of 100 consecutive attempts. *Eur J Obstet Gynecol Reprod Biol* 2018;231:210–3.
 20. McLaren RA Jr, Atallah F, Fisher N, Minkoff H. Maternal and neonatal outcomes after attempted external cephalic version among women with one previous cesarean delivery. *AJP Rep* 2018;8:e349–54. (Level II-2)
 21. Ferguson JE II, Dyson DC. Intrapartum external cephalic version. *Am J Obstet Gynecol* 1985;152:297–8. (Level II-3)
 22. Weiniger CF, Lyell DJ, Tsen LC, Butwick AJ, Shachar B, Callaghan WM, et al. Maternal outcomes of term breech presentation delivery: impact of successful external cephalic version in a nationwide sample of delivery admissions in the United States. *BMC Pregnancy Childbirth* 2016;16:150–9. (Level II-2)
 23. Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, et al. Breech delivery. In: *Williams obstetrics*. 25th ed. New York (NY): McGraw-Hill Education; 2018. p. 539–52. (Level III)
 24. Mahomed K, Seeras R, Coulson R. External cephalic version at term. A randomized controlled trial using tocolysis. *Br J Obstet Gynaecol* 1991;98:8–13. (Level I)
 25. Son M, Roy A, Grobman WA, Miller ES. Association between attempted external cephalic version and perinatal morbidity and mortality. *Obstet Gynecol* 2018;132:365–70. (Level II-2)
 26. Collins S, Ellaway P, Harrington D, Pandit M, Impey LW. The complications of external cephalic version: results from 805 consecutive attempts. *BJOG* 2007;114:636–8. (Level II-3)
 27. Grootscholten K, Kok M, Oei SG, Mol BW, van der Post JA. External cephalic version-related risks: a meta-analysis. *Obstet Gynecol* 2008;112:1143–51. (Meta-analysis)
 28. Dyson DC, Ferguson JE II, Hensleigh P. Antepartum external cephalic version under tocolysis. *Obstet Gynecol* 1986;67:63–8. (Level II-2)
 29. Brocks V, Philipsen T, Secher NJ. A randomized trial of external cephalic version with tocolysis in late pregnancy. *Br J Obstet Gynaecol* 1984;91:653–6. (Level II-1)
 30. Stine LE, Phelan JP, Wallace R, Eglinton GS, van Dorsten JP, Schiffrin BS. Update on external cephalic version performed at term. *Obstet Gynecol* 1985;65:642–6. (Level II-3)



31. Robertson AW, Kopelman JN, Read JA, Duff P, Magelsen DJ, Dashow EE. External cephalic version at term: is a tocolytic necessary? *Obstet Gynecol* 1987;70:896–9. (Level I)
32. Thunedborg P, Fischer-Rasmussen W, Tollund L. The benefit of external cephalic version with tocolysis as a routine procedure in late pregnancy. *Eur J Obstet Gynecol Reprod Biol* 1991;42:23–7. (Level II-3)
33. Kasule J, Chimbira TH, Brown IM. Controlled trial of external cephalic version. *Br J Obstet Gynaecol* 1985;92:14–8. (Level I)
34. Calhoun BC, Edgeworth D, Brehm W. External cephalic version at a military teaching hospital: predictors of success. *Aust N Z J Obstet Gynaecol* 1995;35:277–9. (Level II-3)
35. Lau TK, Lo KW, Wan D, Rogers MS. Predictors of successful external cephalic version at term: a prospective study. *Br J Obstet Gynaecol* 1997;104:798–802. (Level II-3)
36. Hellstrom AC, Nilsson B, Stange L, Nylund L. When does external cephalic version succeed? *Acta Obstet Gynecol Scand* 1990;69:281–5. (Level II-3)
37. Marchick R. Antepartum external cephalic version with tocolysis: a study of term singleton breech presentations. *Am J Obstet Gynecol* 1988;158:1339–46. (Level II-2)
38. Hofmeyr GJ, Sadan O, Myer IG, Galal KC, Simko G. External cephalic version and spontaneous version rates: ethnic and other determinants. *Br J Obstet Gynaecol* 1986;93:13–6. (Level II-2)
39. Mauldin JG, Mauldin PD, Feng TI, Adams EK, Durkalski VL. Determining the clinical efficacy and cost savings of successful external cephalic version. *Am J Obstet Gynecol* 1996;175:1639–44. (Level II-3)
40. Donald WL, Barton JJ. Ultrasonography and external cephalic version at term. *Am J Obstet Gynecol* 1990;162:1542–5; discussion 1545–7. (Level II-3)
41. Healey M, Porter R, Galimberti A. Introducing external cephalic version at 36 weeks or more in a district general hospital: a review and an audit. *Br J Obstet Gynaecol* 1997;104:1073–9. (Level II-3)
42. Shalev E, Battino S, Giladi Y, Edelstein S. External cephalic version at term—using tocolysis. *Acta Obstet Gynecol Scand* 1993;72:455–7. (Level II-3)
43. Newman RB, Peacock BS, VanDorsten JP, Hunt HH. Predicting success of external cephalic version. *Am J Obstet Gynecol* 1993;169:245–9; discussion 249–50. (Level II-3)
44. Tan GW, Jen SW, Tan SL, Salmon YM. A prospective randomised controlled trial of external cephalic version comparing two methods of uterine tocolysis with a non-tocolysis group. *Singapore Med J* 1989;30:155–8. (Level I)
45. Wong WM, Lao TT, Liu KL. Predicting the success of external cephalic version with a scoring system. A prospective, two-phase study. *J Reprod Med* 2000;45:201–6. (Level II-3)
46. Chan LY, Leung TY, Fok WY, Chan LW, Lau TK. High incidence of obstetric interventions after successful external cephalic version. *BJOG* 2002;109:627–31. (Level II-3)
47. Fernandez CO, Bloom SL, Smulian JC, Ananth CV, Wendel GD Jr. A randomized placebo-controlled evaluation of terbutaline for external cephalic version. *Obstet Gynecol* 1997;90:775–9. (Level I)
48. Morrison JC, Myatt RE, Martin JN Jr, Meeks GR, Martin RW, Bucovaz ET, et al. External cephalic version of the breech presentation under tocolysis. *Am J Obstet Gynecol* 1986;154:900–3. (Level II-3)
49. Carlan SJ, Dent JM, Huckaby T, Whittington EC, Shaefer D. The effect of epidural anesthesia on safety and success of external cephalic version at term. *Anesth Analg* 1994;79:525–8. (Level II-3)
50. Bewley S, Robson SC, Smith M, Glover A, Spencer JA. The introduction of external cephalic version at term into routine clinical practice. *Eur J Obstet Gynecol Reprod Biol* 1993;52:89–93. (Level II-3)
51. Lau TK, Stock A, Rogers M. Fetomaternal haemorrhage after external cephalic version at term. *Aust N Z J Obstet Gynaecol* 1995;35:173–4. (Level III)
52. Hanss JW Jr. The efficacy of external cephalic version and its impact on the breech experience. *Am J Obstet Gynecol* 1990;162:1459–63; discussion 1463–4. (Level II-3)
53. Chung T, Neale E, Lau TK, Rogers M. A randomized, double blind, controlled trial of tocolysis to assist external cephalic version in late pregnancy. *Acta Obstet Gynecol Scand* 1996;75:720–4. (Level I)
54. Cluver C, Gyte GM, Sinclair M, Dowswell T, Hofmeyr GJ. Interventions for helping to turn term breech babies to head first presentation when using external cephalic version. *Cochrane Database of Systematic Reviews* 2015, Issue 2. Art. No.: CD000184. DOI: 10.1002/14651858.CD000184.pub4. (Meta-analysis)
55. Cook HA. Experience with external cephalic version and selective vaginal breech delivery in private practice. *Am J Obstet Gynecol* 1993;168:1886–9; discussion 1889–90. (Level II-3)
56. Lau TK, Lo KW, Rogers M. Pregnancy outcome after successful external cephalic version for breech presentation at term. *Am J Obstet Gynecol* 1997;176:218–23. (Level II-2)
57. Wax JR, Sutula K, Lerer T, Steinfeld JD, Ingardia CJ. Labor and delivery following successful external cephalic version. *Am J Perinatol* 2000;17:183–6. (Level II-2)
58. Ben-Haroush A, Perri T, Bar J, Yogev Y, Bar-Hava I, Hod M, et al. Mode of delivery following successful external cephalic version. *Am J Perinatol* 2002;19:355–60. (Level II-2)
59. Vezina Y, Bujold E, Varin J, Marquette GP, Boucher M. Cesarean delivery after successful external cephalic version of breech presentation at term: a comparative study. *Am J Obstet Gynecol* 2004;190:763–8. (Level II-2)
60. Clock C, Kurtzman J, White J, Chung JH. Cesarean risk after successful external cephalic version: a matched, retrospective analysis. *J Perinatol* 2009;29:96–100. (Level II-2)
61. Kuppens SM, Hutton EK, Hasaart TH, Aichi N, Wijnen HA, Pop VJ. Mode of delivery following successful external cephalic version: comparison with spontaneous cephalic presentations at delivery. *J Obstet Gynaecol Can* 2013;35:883–8. (Level II-2)



62. Boujenah J, Fleury C, Bonneau C, Pharisien I, Tigaizin A, Carbillon L. Successful external cephalic version is an independent factor for caesarean section during trial of labor—a matched controlled study. *J Gynecol Obstet Hum Reprod* 2017;46:737–42. (Level II-2)
63. de Hundt M, Velzel J, de Groot CJ, Mol BW, Kok M. Mode of delivery after successful external cephalic version: a systematic review and meta-analysis. *Obstet Gynecol* 2014;123:1327–34. (Systematic Review and Meta-Analysis)
64. Schorr SJ, Speights SE, Ross EL, Bofill JA, Rust OA, Norman PF, et al. A randomized trial of epidural anesthesia to improve external cephalic version success. *Am J Obstet Gynecol* 1997;177:1133–7. (Level I)
65. Neiger R, Hennessy MD, Patel M. Reattempting failed external cephalic version under epidural anesthesia. *Am J Obstet Gynecol* 1998;179:1136–9. (Level III)
66. Dugoff L, Stamm CA, Jones OW III, Mohling SI, Hawkins JL. The effect of spinal anesthesia on the success rate of external cephalic version: a randomized trial. *Obstet Gynecol* 1999;93:345–9. (Level I)
67. Weiniger CF, Ginosar Y, Elchalal U, Sela HY, Weissman C, Ezra Y. Randomized controlled trial of external cephalic version in term multiparae with or without spinal analgesia. *Br J Anaesth* 2010;104:613–8. (Level I)
68. Magro-Malosso ER, Saccone G, Di Tommaso M, Mele M, Berghella V. Neuraxial analgesia to increase the success rate of external cephalic version: a systematic review and meta-analysis of randomized controlled trials [published erratum appears in *Am J Obstet Gynecol* 2017;216:315]. *Am J Obstet Gynecol* 2016;215:276–86. (Systematic Review and Meta-Analysis)
69. Gifford DS, Keeler E, Kahn KL. Reductions in cost and cesarean rate by routine use of external cephalic version: a decision analysis. *Obstet Gynecol* 1995;85:930–6. (Level III)
70. Tan JM, Macario A, Carvalho B, Druzin ML, El-Sayed YY. Cost-effectiveness of external cephalic version for term breech presentation. *BMC Pregnancy Childbirth* 2010;10:3. (Cost-effectiveness analysis)
71. Yamasato K, Kaneshiro B, Salcedo J. Neuraxial blockade for external cephalic version: cost analysis. *J Obstet Gynaecol Res* 2015;41:1023–31. (Decision Analysis)



Published online on April 23, 2020.

Copyright 2020 by the American College of Obstetricians and Gynecologists. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, posted on the internet, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

**American College of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC 20024-2188**

External Cephalic Version. ACOG Practice Bulletin No. 221. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2020;135:e203-12.

The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 1981–October 2014. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles. When reliable research was not available, expert opinions from obstetrician–gynecologists were used.

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:

- I Evidence obtained from at least one properly designed randomized controlled trial.
- II-1 Evidence obtained from well-designed controlled trials without randomization.
- II-2 Evidence obtained from well-designed cohort or case–control analytic studies, preferably from more than one center or research group.
- II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.
- III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:

Level A—Recommendations are based on good and consistent scientific evidence.

Level B—Recommendations are based on limited or inconsistent scientific evidence.

Level C—Recommendations are based primarily on consensus and expert opinion.



This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on acog.org or by calling the ACOG Resource Center.

While ACOG makes every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

All ACOG committee members and authors have submitted a conflict of interest disclosure statement related to this published product. Any potential conflicts have been considered and managed in accordance with ACOG’s Conflict of Interest Disclosure Policy. The ACOG policies can be found on acog.org. For products jointly developed with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product.

